Commercial Intelligence Agents for Blotting Innovations

AI-driven market analysis identifying high-value targets across US pharma, biotech, and academic research for BI's G96 high-throughput Western blotting platform.

Prepared ForCameron Zadeh, COO
Prepared ByRevenue Catalyst
DateMarch 2026
ProductsG96 Precast Gel, G48 Precast Gel, HT-1 Horizontal Tank
Traditional Gel
10-12 samples per run
vs
ABCDEFGH123456789101112
G96 Precast Gel
96 samples per run | Multichannel pipette compatible

Same antibodies. Same buffers. Same protocols. 8x the throughput at 85% lower cost.

How to Navigate This Report
1 Industry Targets 2 Academic Targets 3 Competitive 4 AACR Deep Dive 5 Next Steps

Customer Discovery: What Matters to Each Buyer Persona

28 interviews across Influencers, End Users, and Buyers. These priorities directly inform the messaging hooks throughout this report.

High-throughput Accuracy Affordability Low Human Error Reproducibility Consistency Standardization Quantitation Material Reduction Turnaround Time Automation
Influencer
End User
Buyer

Source: Confidential

Industry Target Accounts

5 US pharma, biotech, and CDMO organizations - plus additional high-value segments including CROs, government labs, and large biotech R&D. More where this came from.

Selection Methodology

These 10 accounts were selected based on three criteria, not ranked by Western blot volume alone:

Timing Signals
Recent events creating near-term buying windows: new facility buildouts, M&A transitions, leadership changes, grant awards, and active hiring in analytical roles.
Analytical Volume
Confirmed high-volume Western blot workflows: CDMO release testing, core facility throughput, drug screening programs, and protein characterization at scale.
Geographic Diversity
Coverage across major US biotech hubs: Research Triangle, Boston, NY/NJ, Houston, Tampa, Nashville, Seattle, and Kansas City.

Western blotting is used in virtually every life science research lab and biopharma QC operation in the US. These 10 accounts are a curated starting point based on current signals - not a comprehensive ranking. A Growth Marketing engagement with RC would expand this to your full addressable market, refine the ICP based on your sales data, and continuously surface new targets as signals emerge.

Opportunity Sizing

Each target account is sized by estimated Western blot volume and potential adoption scope for BI's G96 platform:

XL
Enterprise-scale analytical operations. Hundreds of blots per month across multiple programs. Department or facility-wide adoption potential.
L
Significant analytical volume. Dozens of blots per month. Team or core facility adoption potential.
M
Moderate volume. Regular WB usage in focused research programs. Single lab or small team adoption.
S
Targeted use case. Occasional WB for specific projects. Individual researcher adoption.

FUJIFILM Diosynth Biotechnologies

Holly Springs, NC | $3.2B campus investment | Adding 680 jobs
New Facility Hiring

Signal

Opened $3.2B biomanufacturing campus (Sep 2025) with six 20,000L bioreactors. Additional $1.6B expansion operational in 2026. Hiring QC scientists.

So What: Every new client program requires analytical method transfer and QC release testing. G96 runs 96 conditions simultaneously during method validation - vs 12-15 on traditional gels.
XL
Industrial-scale QC across dozens of active CDMO programs
Chelsea Barrios LinkedIn chelsea.barrios@fujifilm.com
Senior QC Associate
End User
"You're running release testing for multiple client programs simultaneously at Holly Springs. When each new program requires method transfer validation, the G96 lets you run 96 conditions in a single gel - same Tris-HCl buffers, multichannel pipette loading, done in an hour."
Ryan Dross LinkedIn ryan.dross@fujifilm.com
Scientist II, Analytical Development
End User
"When you're transferring analytical methods for new client programs, the G96 lets you validate 96 conditions in a single run - same buffers, same workflow, 8x the data."
Cameron Altieri LinkedIn cameron.altieri@fujifilm.com
QC Sr. Specialist, Instrumentation
Buyer
"You design qualification protocols and set up new analytical labs at Holly Springs. The G96 needs zero new infrastructure - one $800 tank, standard power supply, done."

Regeneron Pharmaceuticals

Tarrytown, NY | $14.3B revenue | ~15,200 employees
Expansion Pipeline

Signal

$7B+ US capex for manufacturing and research. $6B R&D budget in 2026. $3B manufacturing deal with FUJIFILM. Hiring Protein Development Scientists.

So What: 80+ biologic programs generate thousands of Western blots monthly for characterization and screening. G96 is purpose-built for high-throughput clone screening and process development.
XL
80+ biologic programs, global analytical operations
Saleem Alhumaidi LinkedIn saleem.alhumaidi@regeneron.com
Senior Associate Scientist, Protein Development
End User
"Regeneron's PAPD team runs characterization across 80+ biologic programs. When you're screening clones or running SDS-PAGE for protein identity, the G96 gives you 96 samples per gel at $35 - no capital equipment justification needed."
Jethro Prinston LinkedIn jethro.prinston@regeneron.com
Sr Associate Scientist, Protein Biochemistry
End User
"The G96 delivers reproducible results across 96 wells using your existing Tris-HCl protocols - reducing the hands-on time for every characterization run."
Robert Salzler LinkedIn robert.salzler@regeneron.com
Bioanalytical & Biomarker Technologies
End User
"Your immunopeptidomics and protein work involves gel-based separations. The G96 runs 96 samples per gel with your existing Tris-HCl protocols."

KBI Biopharma

Durham, NC | ~$592M revenue | JSR Life Sciences
Hiring Expansion

Signal

RTP facility scaling from 200 to 350+ employees. Peter Carbone promoted to COO (Sep 2024). Actively hiring analytical scientists. Claims 25% faster analytical timelines.

So What: KBI's identity is built on analytical excellence. G96 lets them run 8x more blots per run during method development and release testing.
L
Pure-play analytical CDMO scaling aggressively
Stewart Earnest LinkedIn searnest@kbibiopharma.com
Scientist 1, Analytical Development
End User
"KBI built its reputation on analytical speed - 25% faster timelines than competitors. The G96 is the next multiplier: 96 samples per gel loaded with your 12-channel pipette, same Tris-HCl chemistry your methods already validate with."
Edward Lilla, PhD LinkedIn elilla@kbibiopharma.com
Project Leader / Scientist II
Buyer
"As Project Leader, you know the throughput bottleneck in analytical development. The G96 at $35/gel eliminates it for Western blots."
Ricardo Belloso LinkedIn rbelloso@kbibiopharma.com
Associate Scientist, Analytical Development
End User
"Running analytical methods across client programs at the bench. The G96 at $35/gel gives you 96 samples loaded with a multichannel pipette in under an hour."

Samsung Biologics America

Rockville, MD | ~$3.9B revenue globally | 30% YOY growth
M&A New Facility

Signal

Acquired GSK's Rockville facility for $280M (closing Q1 2026). Retained 500+ employees. First US manufacturing base.

So What: Standing up US CDMO operations from an acquisition means re-validating analytical methods for new client programs. G96 accelerates method transfer validation.
L
New US entry with aggressive growth mandate
Jose Robles LinkedIn jose.robles@samsung.com
QC Microbiology Manager
Buyer
"You're standing up QC operations at Samsung Biologics' first US site. Every new client program needs validated analytical methods - the G96 runs 96 conditions in a single gel, accelerating method transfer validation from days to hours."
Rachel Jung LinkedIn r.jung@samsung.com
Senior Scientist, Manufacturing Science & Technology
Influencer
"Your MSAT team evaluates analytical platforms for tech transfer. The G96 uses the same Tris-HCl buffers and protocols your team already runs - zero method redevelopment, 8x the throughput per gel."
Vincenzo Caruso LinkedIn v.caruso@samsung.com
QC Microbiology, Biopharm Manufacturing
End User
"You led the Green Labs initiative and know the Rockville QC floor. The G96 cuts consumable cost per sample by 85% and eliminates 7 out of 8 gel runs - fewer gels, less waste, same results."

Catalent Biologics

Kansas City, MO | Acquired by Novo Holdings for $16.5B
M&A Hiring

Signal

New ownership (Novo Holdings, Dec 2024). Kansas City undergoing $12M lab expansion for ADC and advanced modality analytical services. Hiring analytical scientists.

So What: KC is Catalent's Center of Excellence for biologics analytical services - they run blots for dozens of clients simultaneously. New capital + lab expansion = buying window.
L
Dedicated biologics analytical center of excellence
Samuel Dedert LinkedIn samuel.dedert@catalent.com
Senior Associate Scientist, Bioanalytics
End User
"As Method Lead, you order supplies and coordinate testing. The G96 at $35/gel cuts your per-sample Western blot cost by 85% while multiplying throughput."
Sayema Khan Tuli, PhD LinkedIn sayema.tuli@catalent.com
Scientist-Biologics II
End User
"Your biologics analytical work at the KC Center of Excellence demands consistent, reproducible results across client programs. The G96 delivers CV under 20% across 96 wells."
John Rockwell LinkedIn john.rockwell@catalent.com
Manager, Biologics Analytical
Buyer
"Your KC analytical team runs blots for dozens of client programs. The G96 reduces consumable cost per sample by 85% - direct margin impact on every batch."

Additional High-Value Segments

Beyond CDMOs, BI's G96 platform has strong fit across multiple market segments: CROs (Charles River, WuXi AppTec US labs) running analytical assays at industrial volume. Large Biotech R&D (Genentech, Amgen) with thousands of bench scientists across oncology, immunology, and protein science. Government Labs (NIH intramural programs at NCI, NIAID) where one adoption decision can standardize across entire divisions. These segments expand BI's addressable market well beyond the 5 accounts above.

Signal Activity Across the US

Industry and academic targets plotted by location. Biotech hub density reveals where BI's go-to-market efforts will have the highest concentration of opportunities.

Fred Hutch Regeneron Dana-Farber Samsung Biologics KBI Biopharma FUJIFILM Diosynth Vanderbilt Catalent MD Anderson Moffitt
Industry Targets
Academic Targets
XL Opportunity
L Opportunity

Academic Target Accounts

5 NCI-designated cancer centers and major research institutions with high-volume Western blot workflows, active core facilities, and recent funding signals. These institutions shape purchasing decisions for hundreds of individual labs.

UT MD Anderson Cancer Center

Houston, TX | NCI Comprehensive Cancer Center | #1 ranked
Grant Award

Signal

Nearly $23M in CPRIT funding (Feb 2025) plus $29M+ (Nov 2025) for cancer research and core facility expansion. Two new core facilities established.

So What: The Functional Proteomics RPPA Core already runs 96-well format protein quantification. G96 fits as a complementary validation tool for RPPA hits at matching throughput.
XL
Core facility adoption serving hundreds of labs institution-wide
Qinghua Yu qyu@mdanderson.org
Research Lab Manager, RPPA Core
Buyer
"Your RPPA Core already operates in 96-well format for high-throughput protein quantification. The G96 gives your researchers a matching-throughput Western blot - 96 wells, multichannel pipette compatible, $35 per gel."
Shuangxing Yu syu@mdanderson.org
Sr. Research Scientist, RPPA Core
End User
"The G96 runs 96 samples with standard multichannel pipettes - same workflow your core already uses for high-throughput assays."
Thisawin Dang LinkedIn tdang@mdanderson.org
Research Assistant / Lab Manager, GU Medical Oncology
Buyer
"You manage day-to-day lab operations and supplies. The G96 is a $35 consumable that replaces a stack of traditional gels - multichannel pipette compatible."

Dana-Farber Cancer Institute / Harvard Cancer Center

Boston, MA | NCI Comprehensive Cancer Center | Largest US consortium
New Center

Signal

New 450,000 sq ft cancer hospital approved (Jun 2025). Largest-ever single gift received (early 2026). Major expansion of research capacity.

So What: Institutional expansion = new lab space, new equipment budgets. Cancer signaling labs (PI3K, kinase pathways) are heavy WB users studying dose-response curves.
XL
Core facility + dozens of signaling labs across the Harvard cancer consortium
Serena Landini LinkedIn serena_landini@dfci.harvard.edu
Principal Research Technician
Buyer
"You manage supplies and protocols for your research team. The G96 replaces a stack of Mini-PROTEAN gels with one $35 gel - 96 samples loaded with a multichannel pipette. Your annual WB consumable spend drops by 85%."
Harrison Olszewski LinkedIn harrison_olszewski@dfci.harvard.edu
Senior Research Technician
End User
"Running Western blots daily in a signaling lab. The G96 lets you screen 96 conditions per gel with the same antibodies you already have validated."
Sudarsana Addepalli LinkedIn sudarsana_addepalli@dfci.harvard.edu
Research Technician, Freed-Pastor Lab
End User
"Your pancreatic cancer research involves protein characterization across multiple conditions. The G96 runs 96 samples in one gel."

H. Lee Moffitt Cancer Center

Tampa, FL | NCI Comprehensive Cancer Center
Publication Volume

Signal

Keiran Smalley's lab published 3 major cancer signaling papers in 2025 (MEK inhibitor, RAS(ON) inhibitor, checkpoint combinations). John Koomen co-authored cancer drug resistance signaling research (Dec 2025).

So What: High-volume WB publications = active, ongoing consumable demand. Labs publishing 3+ WB-heavy papers per year are running hundreds of blots annually.
L
Multiple signaling labs + proteomics core
Bin Fang, PhD bin.fang@moffitt.org LinkedIn
Core Manager, Proteomics Core
Buyer
"Your Proteomics Core standardizes protocols for the entire institution. The G96 is a $35 consumable that gives your users 96-sample Western blots with no new equipment."
Victoria Izumi vicky.izumi@moffitt.org LinkedIn
Core Research Specialist, Proteomics Core
End User
"Your sample prep and protein characterization work generates high-volume blots. The G96 reduces hands-on time per experiment by 8x."
Hong Zheng LinkedIn hong.zheng@moffitt.org
Research Scientist / Lab Manager
Buyer
"Your signal transduction and immuno-oncology work generates high-volume Western blots. The G96 delivers 96 samples per run - same chemistry, 8x throughput."

Vanderbilt-Ingram Cancer Center

Nashville, TN | NCI Comprehensive Cancer Center
New Center

Signal

New Center for Computational and Systems Biology launched Jan 2025. William Tansey appointed Associate Director for Shared Resources (Sep 2025) overseeing 10 shared resources.

So What: New shared resource leadership = fresh evaluation of technologies and vendor relationships. CCSB creates demand for high-throughput validation of computational predictions.
L
40+ cancer cell biology investigators + new systems biology center
Kristie Rose, PhD kristie.rose@vanderbilt.edu
Assoc. Director Proteomics Core
Buyer
"Your core standardizes protein analysis methods for the cancer center. The G96 at $35/gel gives researchers 96-well Western blots with standard Tris-HCl chemistry."
Paula Gonzalez Ericsson LinkedIn paula.gonzalez-ericsson@vanderbilt.edu
Research Asst. Professor / Co-Director Multiplex Core
End User
"Your work developing standardized biomarker methods aligns perfectly with the G96's reproducible 96-well format."
Joseph Serrenho LinkedIn joseph.a.serrenho@vanderbilt.edu
PhD Student, Balko Lab (Cancer Biology)
End User
"Your breast cancer immunotherapy research in the Balko Lab means running signaling pathway Westerns daily. The G96 gives you a full dose-response matrix in one gel."

Fred Hutchinson Cancer Center

Seattle, WA | NCI Comprehensive Cancer Center
Core Facility

Signal

Sloan Precision Oncology Institute expanded to $100M+ (Jul 2025). TakePART-NW precision oncology program launched (Mar 2025). 300,000+ sq ft new research space acquired.

So What: $100M+ in precision oncology = new labs being equipped from scratch. Functional precision oncology requires testing drug responses across patient samples - a perfect G96 use case.
L
New institute with expanding capacity + proteomics shared resource
Phil Gafken, PhD pgafken@fredhutch.org
Sr. Staff Scientist & Director, Proteomics Core
Buyer
"Your proteomics core serves three institutions. The G96 at $35/gel gives users 96-sample Western blots at a fraction of per-sample cost."
Chenwei Lin, PhD LinkedIn clin@fredhutch.org
Staff Scientist, Proteomics Core
End User
"Your mass spec sample prep involves gel-based separations. The G96 runs 96 samples with standard Tris-HCl - same workflow, higher throughput."

Competitive Landscape

Where BI fits in the Western blotting market - and how to position the G96 against established players.

Vendor Key Products Approach Price Point G96 Advantage
Bio-Rad Mini-PROTEAN TGX, ChemiDoc Traditional vertical precast gels $4-8/lane, $2-5K imagers 8x throughput at lower per-sample cost. Same Tris-HCl chemistry.
Bio-Techne / ProteinSimple Jess, Leo System Capillary-based automated Western $50K+ instruments, $15-25/sample Real gel-based results at 1/1000th the instrument cost. Researchers keep familiar workflow.
Thermo Fisher (Invitrogen) NuPAGE, Bolt, iBright Traditional vertical + AI imaging $4-8/lane, $5-20K imagers Same throughput advantage as vs Bio-Rad. Compatible with iBright imaging.
Cytiva (GE) Amersham ECL, Amersham Imager Detection reagents + imaging Premium detection reagents G96 works with all Amersham detection reagents. Complementary, not competitive.
LI-COR Odyssey infrared imaging Quantitative near-IR detection $30-60K imagers G96 gels are compatible with fluorescent detection. Complementary for quantitative applications.
BI occupies a unique gap in the market: higher throughput than any traditional precast gel, at a fraction of the cost of automated capillary systems. The G96 doesn't ask researchers to change their workflow - same antibodies, same buffers, same transfer systems, same imaging. The only change is throughput and cost.
$2.1B
Western Blotting Market (2025)
7% CAGR
Market Growth Rate
$50K+
Automated System Entry Price
$835
G96 Full Setup (tank + gels)

AACR 2026 Deep Dive

April 17-22, San Diego Convention Center. 23,000+ attendees. Here's how to make every hour count.

229
Poster presentations mentioning Western blot methodology
160
US-based researchers identified
4 Days
Apr 19 (36) | Apr 20 (79) | Apr 21 (80) | Apr 22 (34)

How we built this: Our AI conference intelligence system scraped all 229 poster abstracts from the AACR 2026 proceedings in under 15 minutes - extracting presenter names, institutions, and methodology context. This is an example of what continuous conference prep looks like as a service.

Cam's Hit List: Top 10 Posters to Visit

Curated from 229 Western blot poster presentations. These 10 US-based researchers represent the highest-value conversations for BI's G96 platform - ranked by throughput pain, institutional value, and fit with BI's value proposition.

Saturday April 19 - 2:00 PM Poster Session
#433 / Board 3 | Section 18 HIT LIST
A robust automated workflow for precise oncoprotein quantification to accelerate targeted degradation and oncology research
Alex M. Strom, Quynh Nguyen, Qiuyan Ma - OriGene Technologies, Rockville, MD
Session: PO.ET02.11 - Novel Therapeutics and Drug Targets 1
WHY: This poster is about improving Western blot workflows - direct competitor/partner intelligence.
#955 / Board 14 | Section 37 HIT LIST
Development of HiBiT tagged high-throughput screening assay for the discovery of SKP2 targeting degraders
Liankun Song, Merry Chai, Matthew Gozon et al. - UC Irvine, CA
Session: PO.PR02.01 - Experimental Chemoprevention
WHY: High-throughput screening lab using WB for validation. Perfect G96 use case.
#559 / Board 11 | Section 23 HIT LIST
Combination of PRMT5 and Mcl-1 inhibitors overcomes immune checkpoint inhibitor resistance
Siqi Wu, Jaylon Aggison et al. - Baylor College of Medicine, Houston, TX
Session: PO.MCB02.02 - Targeting Mitochondria and Metabolic Vulnerabilities
WHY: Multiple pathway WB analysis across drug combinations - throughput bottleneck.
#335 / Board 20 | Section 14 HIT LIST
Inhibition study of protein kinase C-iota mediated signaling pathways in diffuse midline glioma
Radwan Ebna Noor et al. - University of South Florida, Tampa, FL
Session: PO.ET01.04 - Kinase and Signaling Pathway Dependencies
WHY: Multi-pathway signaling WBs (PKC, PI3K, AKT) across conditions.
Monday April 20 - Busiest Day
9:00 AM Poster Session
#1649 / Board 8 | Section 11 HIT LIST
FcRn humanized mice for pharmacokinetics assessment of antibody drugs
Hannah Horton et al. - Biocytogen, Waltham, MA
Session: PO.ET02.05 - Antibody Technologies and Platforms 1
WHY: Antibody company using WB for protein validation - potential OEM/partner.
2:00 PM Poster Session
#3073 / Board 1 | Section 16 HIT LIST
Dickkopf1 as a potential therapeutic target in highly aggressive breast cancers
Mohd Mughees et al. - UT MD Anderson Cancer Center, Houston, TX
Session: PO.ET02.12 - Novel Therapeutics and Drug Targets 2
WHY: MD Anderson researcher (target institution) using WB for target validation.
#3920 / Board 26 | Section 47 HIT LIST
PIK3CA and ARID1A co-altered tumors are sensitive to AKT inhibitor, capivasertib
Rian Engeldinger et al. - Univ. of Wisconsin Madison, WI
Session: PO.CL07.02 - Molecular Targeted Therapy
WHY: Drug sensitivity screening across tumor models - high WB volume per experiment.
Tuesday April 21
9:00 AM Poster Session
#4672 / Board 21 | Section 20 HIT LIST
Neuropeptide Y Y1 receptor inhibition induces autophagy to limit colorectal cancer progression
Sooraj Kakkat et al. - University of South Alabama, Mobile, AL
Session: PO.MCB02.01 - Cell Death Regulation and Therapeutic Resistance
WHY: Autophagy/apoptosis pathway WBs across multiple markers.
2:00 PM Poster Session
#6405 / Board 5 HIT LIST
Small-molecule screening of HiBiT-tagged PAX3::FOXO1 rhabdomyosarcoma cell lines
Soumili Dey et al. - National Cancer Institute, NIH, Bethesda, MD
Near NCI - high-throughput screening with WB validation.
WHY: NIH/NCI high-throughput screening lab. Government procurement = sticky once adopted.
Wednesday April 22 - Last Day
9:00 AM Poster Session
#5796 / Board 23 HIT LIST
Rpn13Pru targeting small molecules induce mitotic arrest in breast cancer
Santwana K C et al. - National Cancer Institute, Bethesda, MD
Near NCI researchers - government lab contact opportunity.
WHY: NCI researcher - government lab entry point for BI.

Competitor and Partner Mapping

Bio-Rad

Competitor + Partnership Opportunity

Confirmed major AACR exhibitor. Presented AACR 2025 poster on 96-well Western blot applications using ChemiDoc Go imager.

Action: Visit booth, reference the Kirmiz et al. poster (#5484), pitch G96 as upstream complement to ChemiDoc imaging.

Risk: Bio-Rad could develop their own 96-well gel. Better to partner now.

Bio-Techne / ProteinSimple

Competitor Intelligence

Exhibited at AACR 2025 (Booth 3049). Leo System positioned as high-throughput automated Western.

Action: Visit booth, collect Leo pricing materials. Position G96 as "real Western blots at high throughput" vs capillary-based approach. $35/gel vs $50K instrument.

Akoya Biosciences

Partnership Opportunity

Confirmed AACR 2026 Spotlight Theater A. Spatial proteomics platforms.

Action: Researchers using spatial proteomics validate findings by Western blot. G96 is the fast validation layer. Explore co-marketing.

Maximizing Impact as a 1-Person Team

Pre-Conference (Now through April 16)

  • April 3: AACR publishes full abstract text in Cancer Research. Search for "western blot" to build poster visit list with specific abstract numbers and board locations.
  • Send LinkedIn connection requests to 10-15 poster presenters whose abstracts mention high-volume Western blot usage.
  • Load G96 demo video on tablet. Print 50 business cards and 25 product one-pagers.

At the Conference

  • Focus on poster sessions, not plenary talks. Posters are where conversations happen.
  • Poster session workflow: Arrive at start time. Presenters stand at their posters for the first 2 hours. Hit the Top 10 list first.
  • The 2-minute pitch: Start by asking about THEIR work. "How many samples did you need to run?" Then: "We've been working on 96-well precast gels. Can I show you a quick video?"
  • Collect contacts aggressively. The goal is NOT to sell at the poster - it's to get permission for a follow-up lunch-and-learn demo.

The Lunch-and-Learn Pipeline

  • At the poster: genuine conversation, show G96 video, ask "Would your lab be interested in seeing this in action?"
  • Same-day follow-up: LinkedIn message referencing their specific research
  • Within 48 hours post-AACR: personalized email with G96 data sheet + ACS Omega publication
  • This is the strategy that Cam has said works best - getting the product in front of researchers who appreciate the uniqueness of the format visually.

Networking

  • Sunday April 19, 6:30-8:00 PM: AACR Networking Hubs (early-career researchers = future PIs who buy equipment)
  • Gaslamp Quarter restaurants for informal networking every evening
  • AACR Oncology Industry Partnering Event (April 16-17): 800 attendees, separate registration

How This Becomes Operational

This report is a snapshot. Here's what it looks like when it runs continuously.

This Report

What you're reading now - a one-time intelligence snapshot identifying 10 target accounts and 229 AACR poster sessions.

Continuous Monitoring

Automated signal detection across your target market. New facility buildouts, hiring signals, grant awards, publications - surfaced before your competitors see them.

Domain Expertise

Your marketing team knows marketing. We know HCLS buyers. The difference between messaging a QC manager vs an analytical scientist vs a procurement director - that's what 60+ years of combined experience delivers.

Conference Intelligence

AACR is just the start. ASBMB, Neuroscience, ASCB, Pittcon - we build your hit list for every event on your calendar so you walk in with a plan.

The Math

What continuous commercial intelligence means for BI's growth.

229
AACR Poster Sessions
referencing Western blot methodology - each one a potential conversation
10
Target Accounts
with named contacts, signals, and persona-matched messaging hooks
56%
Proven Open Rate
from BI's last RC campaign - 2.4x industry average

No new headcount - Intelligence and content built by operators who've sold into these buyers for 18+ years

Domain expertise your team doesn't have - Life science buyer personas, conference strategy, evidence-matched targeting - not generic B2B marketing

Already proven - 2,400 publication-matched leads and 56% open rate from your last campaign with RC

Compounds over time - Each report builds on the last. Signal dedup, market memory, and buyer journey tracking get smarter every month

Conference Sprint

$2,500 one-time
Targeted conference preparation for a single event
  • Target identification from conference abstract databases
  • Poster session hit list with researcher names and institutions
  • Conversation playbooks matched to BI's value proposition
  • Pre-conference LinkedIn outreach sequences
  • Post-conference follow-up email templates

This report's AACR section is an example of what a Conference Sprint delivers.

Growth Marketing Retainer

$2,000-2,500/mo
$19,200-24,000/yr with annual commitment
Domain-specific marketing execution for scientific products
  • Evidence-matched lead list building (publications, grants, conferences)
  • Persona-specific email sequences for scientific buyers
  • Content creation with HCLS domain expertise (CTAs, landing pages, visuals)
  • Campaign management and optimization via Instantly
  • Monthly performance reporting and strategy calls

Built on the same foundation as your 56% open rate campaign - now with AI-powered targeting and content.

Intelligence + Growth

$3,500/mo
$33,600/yr with annual commitment (20% savings)
Continuous market intelligence plus campaign execution
  • Everything in Growth Marketing Retainer
  • Monthly market intelligence report (target accounts, signals, named contacts)
  • Competitive landscape monitoring
  • Conference prep for every event on your calendar
  • Quarterly strategic review
Book a Meeting
Or reach out directly: trey@revenuecatalyst.io or sohiel@revenuecatalyst.io